The best-proven two-drug hypertension regime in primary care
The Filler POEM on WHI best hypertension HBP regime requires
The quoted WHI WOMENS’ HEALTH INITIATIVE HBP study (Wasserteil-
Smoller ea 2004) was merely an analysis of antihypertensive drugs used
in 19 000 women - and gave no specific drug, dose or brand statistics.
So like the ~100 major antihypertensive drug randomised controlled
trials RCTs in ~500 000 patients on Pubmed, WHI cannot be quoted as
definite evidence favouring any combination, or drug to accompany
lowdose LD (co)thiazide.
THIAZIDE PLUS RESERPINE: The exception may arguably be low-dose LD
reserpine: in well over 16 000 patients for up to a mean of 7years, LD
reserpine plus LD thiazide shone whether as first line or last-ditch
add-on (the six Veterans’ randomized controled trials RCTs – 3000
patients- in 30 years; the two 1997 German reserpine RCTs – 400
patients; and observational studies - HDPF 1979 of 11000 patients,
and recently SHEP (Kostis ea 1995) and ALLHAT (Barzilay J 2004).
The ~hundred major anti-HBP trials already reported on Pubmed
confirm without exception that in general it is not the drugs used
sensibly, but the level to which blood pressure is smoothly and
tolerably lowered longterm, that matters to cardiovascular outcomes.
But unlike methyldopa, hydralazine, alpha-, angiotensin- or beta-
blockers, experience and Pubmed search shows that
*serious adverse effect
(SAE) of appropriate thiazide is vanishingly rare (Biron ea CMAJ 1991:
interstitial pneumonitis -average onset time 44minutes from first dose of
thiazide in 30 reported cases, of whom 90% were women);
*no SAEs have apparently been attributed to amlodipine;
* while reserpine in fact protects against serious allergy (Mekori ea
By now after about fifty years, tens of millions of patients must
have received (co)thiazide, and somewhat fewer reserpine; so in sensible
combination dose (the VA study 1982) they are well proven to be among the
most safe effective and widely used drugs ever for chronic disease –
The British National Formulary/ National Health Service and the
World Health Organization Essential Drug Unit do not explain on what
scientific evidence they (unlike eg the USA and RSA Hypertension
Guidelines) dropped lowdose reserpine from their listings ie their
Perhaps the BMJ or it's readers can tell us?
The preliminary ie unpublished ASCOT HBP press releases deserve
(the scores of major hypertension studies are freely available on
Pubmed word search so are not listed here. It will shortly be tabulated
in the public domain on www.monismhealth.com).
Competing interests: No competing interests